Pyra et al. note that their work extends arguments regarding the insufficiency of current PrEP indication guidance and emphasize that improving access should not contribute to any further stigmatization. It is noteworthy that the CDC conducted some of the initial PrEP trials and provided some of the earliest guidance regarding PrEP. The US Food and Drug Administration was one of the first bodies to approve a medication for PrEP. This type of leadership is encouraging and merits confidence that current challenges with PrEP indication guidance are likely to be addressed in short order. Recently, the CDC predicted that in the absence of intervention 1 in 2 Black MSM, 1 in 5 Latinx MSM, and 1 in 11 White MSM will acquire HIV in their lifetimes. Given the high safety and efficacy of PrEP, it is hard to justify communication with any member of these groups that would not support PrEP use.
This work was supported by the National Institute of Mental Health (grant R01MH114692) and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (protocol 159) from the National Institutes of Health (NIH; grant U19HD089881). The work was facilitated by the Emory Center for AIDS Research (grant P30AI050409).
Note. The contents are solely the responsibility of the author and do not necessarily represent the official views of the NIH.
Am J Public Health. 2020;110(3):267-268. © 2020 American Public Health Association